MX394670B - Agentes anticancerigenos y preparacion de los mismos. - Google Patents
Agentes anticancerigenos y preparacion de los mismos.Info
- Publication number
- MX394670B MX394670B MX2019003368A MX2019003368A MX394670B MX 394670 B MX394670 B MX 394670B MX 2019003368 A MX2019003368 A MX 2019003368A MX 2019003368 A MX2019003368 A MX 2019003368A MX 394670 B MX394670 B MX 394670B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- anticancer agents
- compounds
- methods
- family
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398783P | 2016-09-23 | 2016-09-23 | |
| PCT/US2017/052967 WO2018057897A1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003368A MX2019003368A (es) | 2019-09-16 |
| MX394670B true MX394670B (es) | 2025-03-11 |
Family
ID=61690726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003368A MX394670B (es) | 2016-09-23 | 2017-09-22 | Agentes anticancerigenos y preparacion de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858371B2 (enExample) |
| EP (1) | EP3515492B1 (enExample) |
| JP (1) | JP7111722B2 (enExample) |
| KR (1) | KR102646702B1 (enExample) |
| CN (1) | CN109862916A (enExample) |
| AU (1) | AU2017331260B2 (enExample) |
| BR (1) | BR112019005885A2 (enExample) |
| CA (1) | CA3037883A1 (enExample) |
| DK (1) | DK3515492T3 (enExample) |
| IL (1) | IL265521B2 (enExample) |
| MA (1) | MA46291A (enExample) |
| MX (1) | MX394670B (enExample) |
| RU (1) | RU2019111768A (enExample) |
| WO (1) | WO2018057897A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11851441B2 (en) | 2016-09-23 | 2023-12-26 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
| WO2009031999A1 (en) * | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 and analogs with antitumor activity and method for their preparation |
| CN101417934B (zh) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | 分离自牛樟芝萃取物的化合物 |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| WO2009155606A1 (en) * | 2008-06-21 | 2009-12-23 | St. Jude Children's Research Hospital | Anticancer compounds and methods of making and using same |
| US20150025017A1 (en) * | 2012-02-28 | 2015-01-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating cancer |
| MX340090B (es) * | 2012-11-05 | 2016-06-23 | Pfizer | Analogos de spliceostatina. |
| WO2014100367A1 (en) * | 2012-12-21 | 2014-06-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| US20140274979A1 (en) * | 2013-03-13 | 2014-09-18 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
| CN105611930B (zh) | 2013-07-15 | 2021-03-02 | 亥姆霍兹慕尼黑中心-德国环境与健康研究中心（股份有限公司） | 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物 |
| KR102092569B1 (ko) * | 2013-09-17 | 2020-03-25 | 엘지디스플레이 주식회사 | 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법 |
| US10000505B2 (en) | 2013-11-19 | 2018-06-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| EP3468976A4 (en) * | 2016-06-08 | 2019-11-27 | William Marsh Rice University | DERIVATIVES OF THAILANSTATIN A, METHOD FOR THE TREATMENT AND METHOD FOR SYNTHESIS THEREOF |
| AU2017331260B2 (en) | 2016-09-23 | 2024-11-07 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2017
- 2017-09-22 AU AU2017331260A patent/AU2017331260B2/en active Active
- 2017-09-22 KR KR1020197011144A patent/KR102646702B1/ko active Active
- 2017-09-22 MX MX2019003368A patent/MX394670B/es unknown
- 2017-09-22 RU RU2019111768A patent/RU2019111768A/ru unknown
- 2017-09-22 DK DK17853991.2T patent/DK3515492T3/da active
- 2017-09-22 IL IL265521A patent/IL265521B2/en unknown
- 2017-09-22 CN CN201780065546.7A patent/CN109862916A/zh active Pending
- 2017-09-22 CA CA3037883A patent/CA3037883A1/en active Pending
- 2017-09-22 BR BR112019005885-0A patent/BR112019005885A2/pt unknown
- 2017-09-22 US US16/335,378 patent/US10858371B2/en active Active
- 2017-09-22 MA MA046291A patent/MA46291A/fr unknown
- 2017-09-22 JP JP2019537750A patent/JP7111722B2/ja active Active
- 2017-09-22 WO PCT/US2017/052967 patent/WO2018057897A1/en not_active Ceased
- 2017-09-22 EP EP17853991.2A patent/EP3515492B1/en active Active
-
2020
- 2020-11-09 US US17/092,829 patent/US11851441B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11851441B2 (en) | 2016-09-23 | 2023-12-26 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102646702B1 (ko) | 2024-03-11 |
| RU2019111768A (ru) | 2020-10-23 |
| IL265521A (en) | 2019-05-30 |
| IL265521B1 (en) | 2024-05-01 |
| WO2018057897A1 (en) | 2018-03-29 |
| IL265521B2 (en) | 2024-09-01 |
| US20190218228A1 (en) | 2019-07-18 |
| MA46291A (fr) | 2019-07-31 |
| US20210395265A1 (en) | 2021-12-23 |
| AU2017331260A1 (en) | 2019-05-16 |
| EP3515492A1 (en) | 2019-07-31 |
| CN109862916A (zh) | 2019-06-07 |
| JP2019529563A (ja) | 2019-10-17 |
| MX2019003368A (es) | 2019-09-16 |
| AU2017331260B2 (en) | 2024-11-07 |
| BR112019005885A2 (pt) | 2020-06-02 |
| CA3037883A1 (en) | 2018-03-29 |
| RU2019111768A3 (enExample) | 2020-11-24 |
| EP3515492B1 (en) | 2023-07-26 |
| KR20190077340A (ko) | 2019-07-03 |
| US11851441B2 (en) | 2023-12-26 |
| US10858371B2 (en) | 2020-12-08 |
| EP3515492A4 (en) | 2020-04-08 |
| DK3515492T3 (da) | 2023-08-28 |
| JP7111722B2 (ja) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| CL2017002996A1 (es) | Compuestos alqueno tetrasustituidos y su uso | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| CL2016002516A1 (es) | “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UY36075A (es) | Derivados de tubulisina | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| CL2016002835A1 (es) | “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| CR20180228A (es) | Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma | |
| MX2016016583A (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| MX2016007410A (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| DOP2015000298A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos |